Cargando…

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma

Several biomarkers such as tumor mutation burden (TMB), neoantigen load (NAL), programmed cell‐death receptor 1 ligand (PD‐L1) expression, and lactate dehydrogenase (LDH) have been developed for predicting response to immune checkpoint inhibitors (ICIs) in melanoma. However, some limitations includi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Junjie, Ding, Yongfeng, Wu, Mengjie, Chen, Yanyan, Lyu, Xiadong, Lu, Jun, Wang, Haiyong, Teng, Lisong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666739/ https://www.ncbi.nlm.nih.gov/pubmed/32969604 http://dx.doi.org/10.1002/cam4.3481

Ejemplares similares

Identification of TYROBP and C1QB as Two Novel Key Genes With Prognostic Value in Gastric Cancer by Network Analysis
por: Jiang, Junjie, et al.
Publicado: (2020)

Pan‐cancer analyses reveal that increased Hedgehog activity correlates with tumor immunosuppression and resistance to immune checkpoint inhibitors
por: Jiang, Junjie, et al.
Publicado: (2021)

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors
por: Lu, Shun, et al.
Publicado: (2019)

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
por: Zhang, Wenjing, et al.
Publicado: (2021)

Identification of genes associated with gastric cancer survival and construction of a nomogram to improve risk stratification for patients with gastric cancer
por: Ding, Yongfeng, et al.
Publicado: (2020)

Overexpressed MAGP1 Is Associated With a Poor Prognosis and Promotes Cell Migration and Invasion in Gastric Cancer
por: Wu, Mengjie, et al.
Publicado: (2020)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
por: Buchbinder, Elizabeth I., et al.
Publicado: (2021)

Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018
por: Board, Ruth, et al.
Publicado: (2020)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

Proteomic profiling of gastric cancer with peritoneal metastasis identifies a protein signature associated with immune microenvironment and patient outcome
por: Chen, Yanyan, et al.
Publicado: (2023)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
por: Yin, Xiaoqiang, et al.
Publicado: (2022)

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
por: Mamoor, Maha, et al.
Publicado: (2020)

Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach
por: Jiang, Junjie, et al.
Publicado: (2022)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Predicting Peritoneal Dissemination of Gastric Cancer in the Era of Precision Medicine: Molecular Characterization and Biomarkers
por: Chen, Yanyan, et al.
Publicado: (2020)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2018)

Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival
por: Sussman, Tamara A, et al.
Publicado: (2021)

Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors
por: Sander, Michael S., et al.
Publicado: (2021)

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma
por: Pan, Chaohu, et al.
Publicado: (2023)

Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric Cancer
por: Zhou, Jie, et al.
Publicado: (2019)

Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients
por: Cuzzubbo, Stefania, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases
por: Schlam, Ilana, et al.
Publicado: (2022)

Combining the Fibrinogen/Albumin Ratio and Systemic Inflammation Response Index Predicts Survival in Resectable Gastric Cancer
por: Zhang, Junbin, et al.
Publicado: (2020)

Expression and Prognostic Value of Chromobox Family Proteins in Esophageal Cancer
por: Liu, Jin, et al.
Publicado: (2022)

Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors
por: Gulati, Nicholas, et al.
Publicado: (2021)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
por: Yamada, Tadaaki, et al.
Publicado: (2019)

Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade
por: Natale, Christopher A, et al.
Publicado: (2018)

Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know
por: Braschi-Amirfarzan, Marta, et al.
Publicado: (2017)

Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies
por: Chen, Xuguang, et al.
Publicado: (2021)

Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment
por: Wan, Mingyu, et al.
Publicado: (2022)

BRAF (V600E)/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Colle, Raphael, et al.
Publicado: (2023)

EXOSC5 promotes proliferation of gastric cancer through regulating AKT/STAT3 signaling pathways
por: Chen, Xiangliu, et al.
Publicado: (2022)

Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study
por: Yu, Xiongfei, et al.
Publicado: (2022)

Multi‐cohort analysis identifies somatic NTRK mutations as a biomarker for immune checkpoint inhibitor use in cutaneous melanoma
por: Yan, Junya, et al.
Publicado: (2023)

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions
por: Lord, Christopher J, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qpcnhiekvlepr42lesf0p260gh